Purpose-To update information on cytomegalovirus (CMV) retinitis in patients with the acquired immune deficiency syndrome (AIDS) and to integrate information on its pathogenesis and clinical outcomes.
Design-Literature review.Methods-Selected articles from the medical literature, particularly large epidemiologic studies, including the Johns Hopkins Cytomegalovirus Retinitis Cohort Study, the Longitudinal Study of the Ocular Complications of AIDS, and the Cytomegalovirus Retinitis and Viral Resistance Study, were reviewed. Clinical information is discussed in light of knowledge on CMV, its pathogenesis, and its interactions with human immunodeficiency virus (HIV).Results-Cytomegalovirus uses several mechanisms to evade the immune system and establish latent infection in immunologically normal hosts. With immune deficiency, such as late-stage AIDS, CMV reactivates, is disseminated to the eye, and establishes a productive infection, resulting in retinal necrosis. HIV and CMV potentiate each other: CMV accelerates HIV disease, and CMV retinitis is associated with increased mortality. Randomized clinical trials have demonstrated the efficacy of treatments for CMV retinitis. Systemically-administered treatment for CMV retinitis decreases AIDS mortality. Highly active antiretroviral therapy (HAART), effectively suppresses HIV replication, resulting in immune recovery, which, if sufficient, controls retinitis without anti-CMV therapy. Resistant CMV, detected in the blood, correlates with resistant virus in the eye and is associated with worse clinical outcomes, including mortality. Host factors, including host genetics and access to care, play a role in the development of CMV retinitis. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conclusions-ClinicalOff label use of drugs: Discussion of intravitreal injection of antiviral drugs ganciclovir, foscarnet, and cidofovir.
NIH Public Access
Author ManuscriptAm J Ophthalmol. Author manuscript; available in PMC 2012 February 1.Published in final edited form as: Am J Ophthalmol. 2011 February ; 151(2): 198-216.e1. doi:10.1016/j.ajo.2010.018.
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Epidemiology of Cytomegalovirus RetinitisPrior to the advent of the acquired immune deficiency syndrome (AIDS), cytomegalovirus (CMV) retinitis (Figure 1) was a rare disease seen primarily among transplant patients, but also among those with congenital CMV infection and other forms of immune compromise. 1 -4 It was estimated to affect ~1% of patients undergoing renal transplant and ~0.5% of those undergoing bone marr...